# MiroBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mirobio

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.mirobio.com
- Total disclosed funding: $130M
- Latest round: Series B (Jun 29, 2022)
- Investors on record: 7

## About

MiroBio Ltd is a biotechnology company focused on developing innovative therapies aimed at modulating the immune system. Their expertise lies in creating immune inhibitory receptor agonists to address significant health challenges.MiroBio Ltd, founded in 2019 in Oxford, UK, specializes in immunotherapeutic products. The company has not indicated any major pivots in its strategy or operations. MiroBio was acquired by Gilead Sciences, Inc. on August 4, 2022, for USD 405.00 mn, marking a significant milestone in its growth trajectory. The firm has completed a total of 3 deals, with the last funding round being a Trade Sale, which also represents the total amount raised.The company specializes in a range of innovative products designed to modulate immune responses, specifically focusing on immune inhibitory receptor agonists. These products aim to improve patient outcomes in various immune-related conditions, serving diverse sectors including biotechnology and pharmaceuticals, and have established a clientele across North America, Europe, and Asia.The revenue model of MiroBio Ltd is structured around B2B partnerships with clients engaging through direct sales. Their flagship offerings are available as one-time purchases, ensuring a steady stream of income. MiroBio reported an EBITDA of USD -42.49 mn for the year 2022, reflecting the ongoing investment in product development and market expansion.Following its acquisition by Gilead Sciences, Inc., MiroBio Ltd aims to leverage Gilead’s resources to enhance its proprietary discovery platform and expand its portfolio of immune inhibitory receptor agonists. Plans for future growth include the development of new therapeutics targeting specific immune pathways, with expectations for product launches in the coming years. The recent funding will be utilized to support R&D initiatives and facilitate entry into new markets, particularly targeting regions in Europe and Asia by 2024.

## Funding rounds

- Series B, Jun 29, 2022, $97M — OrbiMed Advisors, SR One, Oxford Sciences Enterprises, Medicxi, Advent Life Sciences, Samsara BioCapital, Monograph Capital
- Series A, Aug 8, 2019, $33M — SR One, Oxford Sciences Enterprises, Advent Life Sciences, Samsara BioCapital

## Investors

- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series A, Series B
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A, Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series B
- Monograph Capital (https://capitalatlas.ai/funds/monograph-capital) — Series B